178 related articles for article (PubMed ID: 20555069)
1. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fey MF; Dreyling M;
Ann Oncol; 2010 May; 21 Suppl 5():v158-61. PubMed ID: 20555069
[No Abstract] [Full Text] [Related]
2. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Fey M; Dreyling M;
Ann Oncol; 2009 May; 20 Suppl 4():100-1. PubMed ID: 19454422
[No Abstract] [Full Text] [Related]
4. MDS researchers seek treatments but find few.
Bankhead C
J Natl Cancer Inst; 2007 Jul; 99(13):996-7. PubMed ID: 17596568
[No Abstract] [Full Text] [Related]
5. [Current treatment options for myelodysplastic syndromes].
Nolte F; Hofmann WK
Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
[No Abstract] [Full Text] [Related]
6. Advances in stem cell transplantation: making it better and safer.
Giralt S
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S293-5. PubMed ID: 19778855
[TBL] [Abstract][Full Text] [Related]
7. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.
Ossenkoppele GJ; van de Loosdrecht AA; Schuurhuis GJ
Br J Haematol; 2011 May; 153(4):421-36. PubMed ID: 21385170
[TBL] [Abstract][Full Text] [Related]
8. Transplant for MDS: challenges and emerging strategies.
Tamari R; Castro-Malaspina H
Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
Fuerst D; Mueller C; Beelen DW; Neuchel C; Tsamadou C; Schrezenmeier H; Mytilineos J
Haematologica; 2016 Feb; 101(2):241-7. PubMed ID: 26611475
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fey MF; Buske C;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi138-43. PubMed ID: 23970018
[No Abstract] [Full Text] [Related]
11. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
12. The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS.
Kako S; Kanda Y; Kato J; Yamamoto W; Kato S; Onizuka M; Yokota A; Tatara R; Yokoyama H; Hagihara M; Usuki K; Gotoh M; Watanabe R; Kawai N; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Hematol Oncol; 2017 Sep; 35(3):341-349. PubMed ID: 26643559
[TBL] [Abstract][Full Text] [Related]
13. Role of hematopoietic stem cell transplantation in acute myelogenous leukemia and myelodysplastic syndrome.
Tallman MS; Mathews V; DiPersio JF
Cancer Treat Res; 2009; 144():415-39. PubMed ID: 19779880
[No Abstract] [Full Text] [Related]
14. Acute myeloblastic leukemia in adult patients: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Fey M; Dreyling M;
Ann Oncol; 2008 May; 19 Suppl 2():ii58-9. PubMed ID: 18456770
[No Abstract] [Full Text] [Related]
15. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
16. Oñate G, Bataller A, Garrido A, et al; CETLAM (Spanish Cooperative Group for the Diagnosis and Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes). Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022;6(3):882-890.
Blood Adv; 2023 Mar; 7(5):875. PubMed ID: 36917130
[No Abstract] [Full Text] [Related]
17. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of acute myeloblastic leukaemia (AML) in adult patients.
Fey MF;
Ann Oncol; 2003 Aug; 14(8):1161-2. PubMed ID: 12881367
[No Abstract] [Full Text] [Related]
18. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Fenaux P; Haase D; Sanz GF; Santini V; Buske C;
Ann Oncol; 2014 Sep; 25 Suppl 3():iii57-69. PubMed ID: 25185242
[No Abstract] [Full Text] [Related]
19. Therapy-related myelodysplastic syndromes.
Park DJ; Koeffler HP
Semin Hematol; 1996 Jul; 33(3):256-73. PubMed ID: 8819235
[No Abstract] [Full Text] [Related]
20. Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Wong E; Mason K; Collins J; Hockridge B; Boyd J; Gorelik A; Szer J; Ritchie DS
Biol Blood Marrow Transplant; 2017 May; 23(5):840-844. PubMed ID: 28167152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
